@Since the beginning of this century, a variety of innovative cancer
therapies have been actively developed world wide. gCancer immunotherapyh
including therapeutic antibodies, cancer vaccines and immune cell therapies
is also one of such newly emerging therapeutic approaches of cancers. Cancer
immunotherapy utilizes gimmunityh that is originally possessed by human
body and is highly specific and effective defense system against threatens
including pathogenic organisms and cancer cells.
@Professor Hiroshi Shiku of Mie University has accumulated a large body of
scientific outcomes from his lifework of studies on the relationship between
cancer and immunity. Based on this, ImmunoFrontier, Inc. aims to develop
innovative immune therapies with higher efficacy and few side effects
against the wide range of cancers, especially the hard-to-treat esophageal,
prostate and lung cancers.
@ImmunoFrontierfs bussiness goals are the following four:
T. Development of gcancer protein vaccinesh employing cancer-specific
proteins as antigens and Cholesteryl Pullulan (CHP) as the antigen delivery
U. Creation of next generation protein drugs using CHP delivery system.
V. R&D of gcancer DNA vaccinesh, which are next generation cancer
W. R&D of the modulators of regulatory T cell functions for the
treatment of intractable immune diseases.
||@To attain these goals and to make these new medicines available to all who
need, ImmunoFrontier, Inc. was established in 2004.